Biopharmaceutical group Hemogenyx Pharmaceuticals plc (LSE: HEMO) announced on Wednesday that it has secured a USD120,000 G-Rex grant from ScaleReady, in partnership with Wilson Wolf Manufacturing and Cell Ready, to optimise and scale manufacturing of its lead CAR-T therapy, HG-CT-1.

Currently in a Phase I trial for relapsed/refractory acute myeloid leukemia in adults, HG-CT-1 will benefit from the development of a closed-system, G-Rex-based manufacturing platform designed to reduce production complexity, streamline regulatory compliance, and lower per-patient costs.

The grant also provides Hemogenyx with expert consulting in lean bioprocessing, regulatory strategy and process engineering, enhancing its clinical and commercial manufacturing readiness. Data generated from the optimisation is expected to support adoption of next-generation G-Rex "M" series bioreactors, enabling greater automation and reduced operator intervention.

Hemogenyx continues to advance clinical and operational goals, with ongoing development of therapies targeting blood and autoimmune diseases and expanding the potential of bone marrow transplantation.